Potassium Iodide
CAS 7681-11-0
Potassium Iodide (CAS 7681-11-0) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 349 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 80000 nM | 1 | - |
| Carbonic anhydrase 4 Enzyme |
Ki | 4.1 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Amaurosis fugax | 53 | 218.397 | 10001903 |
| Urinary tract disorder | 54 | 190.717 | 10046566 |
| Ocular discomfort | 54 | 184.537 | 10052143 |
| Haemorrhagic stroke | 59 | 181.801 | 10019016 |
| Head discomfort | 53 | 144.092 | 10019194 |
| Generalised oedema | 55 | 130.338 | 10018092 |
| Photophobia | 53 | 129.145 | 10034960 |
| Eye pain | 59 | 117.581 | 10015958 |
| Altered state of consciousness | 59 | 116.498 | 10001854 |
| Blindness | 55 | 116.245 | 10005169 |
| Diplopia | 55 | 113.161 | 10013036 |
| Tinnitus | 59 | 108.219 | 10043882 |
| Presyncope | 55 | 106.379 | 10036653 |
| Haematemesis | 56 | 99.169 | 10018830 |
| Ascites | 63 | 95.966 | 10003445 |
| Haematuria | 60 | 93.558 | 10018867 |
| Cardio-respiratory arrest | 66 | 88.954 | 10007617 |
| Coma | 59 | 74.477 | 10010071 |
| Vision blurred | 58 | 61.861 | 10047513 |
| Syncope | 65 | 53.534 | 10042772 |
| Chills | 62 | 52.188 | 10008531 |
| Abdominal pain upper | 73 | 49.706 | 10000087 |
| Tachycardia | 60 | 47.127 | 10043071 |
| Cough | 92 | 46.693 | 10011224 |
| Sepsis | 73 | 41.159 | 10040047 |
| Myalgia | 60 | 40.662 | 10028411 |
| Blood pressure increased | 64 | 38.395 | 10005750 |
| Insomnia | 69 | 37.064 | 10022437 |
| Regurgitation | 12 | 36.225 | 10067171 |
| Somnolence | 63 | 33.73 | 10041349 |
| Hyperthyroidism | 20 | 32.808 | 10020850 |
| Decreased appetite | 76 | 32.347 | 10061428 |
| Exposure during pregnancy | 46 | 30.966 | 10073513 |
| Vitamin B12 deficiency | 13 | 27.981 | 10047609 |
| Oropharyngeal discomfort | 12 | 25.611 | 10068318 |
| Vomiting | 107 | 24.954 | 10047700 |
| Thyrotoxic crisis | 7 | 24.087 | 10043786 |
| Eructation | 13 | 24.019 | 10015137 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| POTASSIUM IODIDE | 8597 | SU | MTHSPL |
| Potassium Iodide | 8597 | SU | MTHSPL |
| potassium iodide | 8597 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Potassium Iodide used for in pharmaceutical contexts?
Potassium Iodide (CAS 7681-11-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Potassium Iodide?
Potassium Iodide has 349 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Amaurosis fugax, Urinary tract disorder, Ocular discomfort, Haemorrhagic stroke, Head discomfort. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Potassium Iodide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Potassium Iodide with EU status "permitted".
What clinical phase is Potassium Iodide in?
Potassium Iodide is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Potassium Iodide?
Potassium Iodide has 2 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 4.